Renin-angiotensin system block and atrial fibrillation.
Atrial fibrillation is the most common disorder of cardiac rhythm. In spite of diagnosis simplicity, patients with atrial fibrillation are difficult to treat. In the recent years with the description of the phenomenon called remodelling, it has been possible to better define the principle mechanisms responsible for initiation, maintenance and, in some instances, termination of atrial fibrillation. Electrical, mechanical and anatomical remodelling indicate those alterations that, once established, may vanish any attempt to restore sinus rhythm. Atrial fibrosis is probably the most critical component of the remodelling process and appears to be largely mediated by the activation of the Renin-Angiotensin-Aldosterone System. Both experimental and clinical data have confirmed the pro-arrhythmic role of the Renin-Angiotensin-Aldosterone System and demonstrated an anti-arrhythmic effects of ACE-inhibitors and AT(1) receptor blockers. Regarding atrial fibrillation, it has been recently reported that the adjunction of AT(1) receptor blocker to amiodarone was more effective than the anti-arrhythmic drug alone, in reducing arrhythmia recurrence after electrical cardioversion. This and subsequent clinical observations indicate that pharmacological interventions capable of interfering with the electrical and structural remodelling process are of critical importance in the management of patients with atrial fibrillation. ACE inhibitors and AT(1) receptor blockers represent new and efficient therapeutical options to contrast the nearly inevitable progression of this arrhythmia towards its permanent form.
Cardiologia, Dipartimento di Medicina, Chirurgia e Odontoiatria, Osp. San Paolo, University of Milan, 20142 Milan, Italy. Federico.Lombard@unimi.it
Federico
F
Lombardi
Paolo
P
Terranova
D000450:Aldosterone / Q000378:metabolism; D000818:Animals; D001281:Atrial Fibrillation / Q000378:metabolism*; D004554:Electric Countershock; D006801:Humans; D007249:Inflammation / Q000378:metabolism; D012084:Renin-Angiotensin System / Q000187:drug effects*; D013379:Substrate Specificity
D000450:Aldosterone